lamivudine has been researched along with raltegravir potassium in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (7.27) | 29.6817 |
| 2010's | 40 (72.73) | 24.3611 |
| 2020's | 11 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, KW; Ferris, R; Foster, SA; Fujiwara, T; Garvey, EP; Hazen, RJ; Johns, BA; Kawasuji, T; Kawauchi-Miki, S; Kobayashi, M; Miki, S; Sato, A; Seki, T; Suyama-Kagitani, A; Taishi, T; Underwood, MR; Wakasa-Morimoto, C; Yoshinaga, T | 1 |
| Crumpacker, CS; Gilde, LR; Gotuzzo, E; Isaacs, RD; Kovacs, C; Markowitz, M; Mendo, F; Miller, MD; Morales-Ramirez, JO; Nguyen, BY; Prada, G; Ratanasuwan, W; Teppler, H; Wan, H; Wenning, LA | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA | 1 |
| Fujimoto, H; Fukutake, K; Funato, K; Hashimoto, Y; Yotsumoto, M | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Hesse, K | 1 |
| Baldelli, F; Floridia, M; Francisci, D; Martinelli, L; Masini, G; Weimer, LE; Zazzi, M | 1 |
| Hoffmann, HH; Kunz, A; Palese, P; Shaw, ML; Simon, VA | 1 |
| Bieniek, B | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Bower, M; Dunning, J; Manley, K; Nelson, M | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Boonchawalit, S; Harada, S; Matsushita, S; Yamaguchi, A; Yoshimura, K; Yusa, K | 1 |
| An, JH; Jang, HC; Jang, MO; Jung, SI; Kang, SJ; Kim, J; Kim, SE; Park, KH | 1 |
| Cauda, R; Digiambenedetto, S; Fabbiani, M; Fortuna, S; Lisi, L; Navarra, P; Ragazzoni, E | 1 |
| Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F | 1 |
| Abraham, T; Saad, N; Wu, G | 1 |
| Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C | 1 |
| Barchiesi, F; Cirioni, O; Fragola, V; Gabrielli, E; Giacometti, A; Marchionni, E; Massella, M; Weimer, LE | 1 |
| Lee, D; Nguyen, NH; Yee, BE | 1 |
| Carda-Broch, S; Casas-Breva, I; Esteve-Romero, J; Peris-Vicente, J; Villareal-Traver, M | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S | 1 |
| Deulina, MO; Ivanova, ES; Kanestri, VG; Kravchenko, AV; Pokrovsky, VV; Popova, AA; Yakovlev, AA; Zimina, VN | 1 |
| Inui, A; Isonuma, H; Naito, T; Saita, M; Suzuki, A; Uehara, Y | 1 |
| Assuied, A; De Castro, N; Fagard, C; Grinsztejn, B; Grondin, C; Molina, JM; Pilotto, JH; Sauvageon, H; Taburet, AM; Veloso, V | 1 |
| Bañón, S; Casado, JL | 1 |
| Gray, LR; Hammarskjold, ML; Rekosh, D; Santos, WL; Tebit, DM; Wynn, JE; Zhang, W | 1 |
| Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M | 1 |
| Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N | 1 |
| Evans, CD; Flynn, DM; Fong, PS; Korthuis, PT | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Calza, L; Concia, E; Cucchetto, G; Lanzafame, M; Lattuada, E; Nicolè, S | 1 |
| Bagenda, L; Bertagnolio, S; Easterbrook, PJ; Hakim, J; Hoppe, A; Kambugu, A; Kiconco, M; Kityo, C; Mugyenyi, P; Nankya, I; Paton, NI; Thompson, J; van Oosterhout, JJ; Walker, AS | 1 |
| Carini, E; Castagna, A; Danise, A; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Muccini, C; Poli, A; Spagnuolo, V | 1 |
| Cotarelo, M; Macías, J; Mancebo, M; Merchante, N; Merino, D; Montes-Ramírez, ML; Pérez-Pérez, M; Pineda, JA; Pulido, F; Raffo, M; Rivero-Juárez, A; Téllez, F | 1 |
| Bachiller, P; Barrufet, P; Boix, V; Cabello, A; Cervero, M; Gómez, C; Matarranz, M; Montejano, R; Ryan, P; Samperiz, G; Santos, I; Sanz, J; Sepúlveda, MA; Solís, J; Troya, J; Valencia, E; Vera, F; Yllescas, M | 1 |
| Bukin, EK; Chounta, V; Garib, SA; Holbrook, T; Piercy, J; Punekar, YS; Tremblay, G | 1 |
| Cabello, A; Cañamares, I; Cuevas, G; Matarranz, M; Montejano, R; Ryan, P; Solís, J; Troya, J; Walther, LÁ | 1 |
| Bragantini, D; Calza, L; Lanzafame, M; Lattuada, E; Nicolè, S; Rizzardo, S; Tacconelli, E | 1 |
| Blanch, J; Blanco, JL; de Lazzari, E; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Lonca, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Plana, M; Rodriguez, A; Rojas, J; Sanchez-Palomino, S; Tricas, A | 1 |
| Antinori, A; Barchi, E; Bonfanti, P; Bonora, S; Borghi, V; Cattelan, AM; D'Ettorre, G; Degli Antoni, A; Di Biagio, A; Focà, E; Francisci, D; Limonta, S; Maggiolo, F; Mussini, C; Nozza, S; Roncaglia, E; Rusconi, S; Segala, D | 1 |
| Anthony, P; Best, BM; Cahn, P; Chakhtoura, N; Chokephaibulkit, K; Cressey, TR; de Lourdes B Teixeira, M; Essack, Z; Frenkel, LM; Fuller, TL; Gouvèa, MIS; Hennessy, R; João, EC; Laimon, L; Mathiba, R; Mirochnick, M; Mmbaga, BT; Moreira, LF; Morrison, RL; Ngocho, JS; Njau, BN; Pilotto, JHS; Prommas, S; Rolon, MJ; Shapiro, DE; Siberry, GK; Violari, A; Werarak, P | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Granozzi, B; Re, MC; Testi, D; Viale, P | 1 |
| Booth, J; Chowdary, P; Khurram, MA; Mohamed, IH; Shetty, S; Yaqoob, M | 1 |
| Hamzah, L; Post, FA | 1 |
| Baldin, G; Borghi, V; Ciccullo, A; Di Giambenedetto, S; Farinacci, D; Guaraldi, G; Lassandro, AP; Mussini, C | 1 |
| Amara, A; Boffito, M; Challenger, E; Dickinson, L; Egan, D; Else, L; Fox, J; Herrera, C; Khoo, S; Lee, M; Lwanga, J; Mantori, S; Penchala, SD; Shattock, R | 1 |
| Jones, S; Loh, C; Majumdar, A; Monaghan, M; Oware, A; Roderick, M; Urankar, K | 1 |
| Capetti, A; Celani, L; Ciccullo, A; Colafigli, M; D'Ettorre, G; De Vito, A; Di Giambenedetto, S; Durante, M; Dusina, A; Fabbiani, M; Lagi, F; Mazzitelli, M; Montagnani, F; Oreni, L; Rossetti, B; Rusconi, S; Sterrantino, G | 1 |
| Benamor Teixeira, ML; Chakhtoura, N; Coombs, RW; Frenkel, LM; Fuller, TL; Gouvêa, MI; Hennessey, R; João, EC; Mirochnick, M; Morrison, RL; Shapiro, DE; Whitson, K | 1 |
| Chen, T; Gui, F; Tan, J; Wei, G; Yang, J; Zhao, Y | 1 |
| Burger, D; Chen, RQ; Colbers, A; Geerlings, S; Zino, L | 1 |
9 review(s) available for lamivudine and raltegravir potassium
| Article | Year |
|---|---|
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Dolutegravir for the treatment of adult patients with HIV-1 infection.
Topics: Adult; Clinical Trials as Topic; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2014 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biological Availability; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Raltegravir Potassium; Tablets | 2015 |
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Drug Substitution; HIV Infections; HIV-1; Humans; Lamivudine; Raltegravir Potassium; Rilpivirine; Treatment Outcome; Viral Load | 2019 |
Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Atovaquone; CD4 Lymphocyte Count; CD4-CD8 Ratio; COVID-19; Dideoxynucleosides; Female; Glucocorticoids; Graft Rejection; HIV Infections; HIV-1; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Male; Middle Aged; Mycophenolic Acid; Pneumonia, Pneumocystis; Prednisolone; Raltegravir Potassium; RNA, Viral; SARS-CoV-2; Tacrolimus; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
Inflammatory Myositis Secondary to Anti-Retroviral Therapy in a Child; Case Report and Review of the Literature.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Female; HIV Infections; Humans; Lamivudine; Myositis; Raltegravir Potassium; Viral Load | 2021 |
16 trial(s) available for lamivudine and raltegravir potassium
| Article | Year |
|---|---|
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Latin America; Male; Middle Aged; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Thailand; Time Factors; Treatment Outcome; United States | 2007 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Lack of a significant drug interaction between raltegravir and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Raltegravir as effective as efavirenz in 144-week data.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome | 2009 |
Variability of raltegravir plasma levels in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir | 2013 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Raltegravir Potassium; Rifampin; Tenofovir; Tuberculosis | 2015 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Public Health; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Elasticity Imaging Techniques; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Raltegravir Potassium; Tenofovir; Triglycerides; Waist-Hip Ratio | 2017 |
A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Lamivudine; Maintenance Chemotherapy; Male; Middle Aged; Pilot Projects; Raltegravir Potassium; Treatment Outcome; Young Adult | 2019 |
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2019 |
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Outcome Assessment, Health Care; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Viral Load; Young Adult; Zidovudine | 2020 |
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pre-Exposure Prophylaxis; Raltegravir Potassium | 2021 |
Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Raltegravir Potassium; Vigna; Viral Load; Virus Shedding; Zidovudine | 2021 |
30 other study(ies) available for lamivudine and raltegravir potassium
| Article | Year |
|---|---|
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Topics: Anti-HIV Agents; Cell Line; Cell Line, Transformed; Drug Resistance, Viral; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Naphthyridines; T-Lymphocytes; Virus Integration; Virus Replication | 2011 |
Central nervous system T-cell lymphoma in acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Brain; Central Nervous System Neoplasms; Humans; Lamivudine; Lymphoma, T-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Pyrrolidinones; Raltegravir Potassium; Stavudine; Treatment Outcome | 2010 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2010 |
HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-2; Humans; Kidney Failure, Chronic; Lamivudine; Male; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Renal Dialysis; Salvage Therapy; Tenofovir; Treatment Outcome | 2011 |
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.
Topics: Animals; Antiviral Agents; Autoradiography; beta-Galactosidase; Carbamates; Cell Line, Tumor; Cell Survival; Chickens; Dihydroorotate Dehydrogenase; DNA Primers; Furans; Humans; Indoles; Lamivudine; Mammals; Nevirapine; Oxadiazoles; Oxidoreductases Acting on CH-CH Group Donors; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Species Specificity; Sulfonamides; Time Factors; Virus Replication; Viruses | 2011 |
[Raltegravir in a special case: patient with HIV and Burkitt's lymphoma].
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; CD4 Lymphocyte Count; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal Neoplasms; HIV Seropositivity; Humans; Intestine, Small; Lamivudine; Lymphoma, AIDS-Related; Male; Pyrrolidinones; Raltegravir Potassium; Remission Induction; Viral Load | 2011 |
HIV-associated gastric natural killer/T-cell lymphoma.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Atazanavir Sulfate; Cyclophosphamide; Doxorubicin; Female; HIV Seropositivity; Humans; Lamivudine; Lymphoma, Extranodal NK-T-Cell; Oligopeptides; Prednisone; Pyridines; Pyrrolidinones; Raltegravir Potassium; Stomach Neoplasms; Vincristine | 2012 |
Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cyclohexanes; DNA, Viral; Genetic Variation; Genotype; Glycosylation; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Molecular Sequence Data; Phylogeny; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; Saquinavir; Sequence Analysis, DNA; Triazoles; Viral Tropism | 2013 |
Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Republic of Korea; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2013 |
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abac
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatine Kinase; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Muscle Weakness; Myalgia; Pyrrolidinones; Raltegravir Potassium; Zidovudine | 2013 |
Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.
Topics: Adolescent; Anti-HIV Agents; Drug Combinations; Drug Hypersensitivity Syndrome; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Lopinavir; Pleural Effusion; Postpartum Period; Pyrrolidinones; Radiography; Raltegravir Potassium; Respiratory Distress Syndrome; Ritonavir; Zidovudine | 2014 |
A micellar liquid chromatography method for the quantification of abacavir, lamivudine and raltegravir in plasma.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Dideoxynucleosides; Lamivudine; Micelles; Plasma; Pyrrolidinones; Raltegravir Potassium; Sodium Dodecyl Sulfate | 2014 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2015 |
[The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection].
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Rifabutin; RNA, Viral; Time Factors; Treatment Outcome; Tuberculosis; Young Adult | 2014 |
Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis.
Topics: Adult; Anti-HIV Agents; Asian People; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Hyperlipidemias; Kidney Function Tests; Lamivudine; Lipids; Liver Function Tests; Male; Middle Aged; Nausea; Pilot Projects; Raltegravir Potassium; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2016 |
Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA.
Topics: Anti-HIV Agents; Boronic Acids; HeLa Cells; HIV Core Protein p24; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Nucleic Acid Conformation; Peptide Library; Peptides; Quinolones; Raltegravir Potassium; Response Elements; RNA, Viral; Structure-Activity Relationship; Virus Replication; Zidovudine | 2016 |
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir | 2016 |
Integrase strand transfer inhibitor-associated diabetes mellitus: A case report.
Topics: Adult; Diabetes Mellitus; Dideoxynucleosides; Drug Combinations; Glycated Hemoglobin; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Raltegravir Potassium | 2017 |
Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Raltegravir Potassium; RNA, Viral; Viral Load | 2017 |
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Raltegravir Potassium; Retrospective Studies; Treatment Outcome; Viral Load | 2018 |
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Retrospective Studies; Treatment Outcome | 2018 |
Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Quality-Adjusted Life Years; Raltegravir Potassium; Russia | 2018 |
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kidney Function Tests; Lamivudine; Liver Function Tests; Male; Middle Aged; Raltegravir Potassium; Treatment Outcome; Triglycerides | 2019 |
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Retrospective Studies; Viral Load | 2020 |
Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir.
Topics: Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin; Lamivudine; Menopause; Nitriles; Oxazines; Piperazines; Pyridones; Pyrimidines; Raltegravir Potassium; Waist Circumference; Weight Gain | 2021 |
Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza
Topics: Adipose Tissue; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium | 2021 |
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
Topics: Adult; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Raltegravir Potassium; Viral Load | 2021 |
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer.
Topics: Amides; Anti-HIV Agents; Colorectal Neoplasms; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Integrase Inhibitors; Lamivudine; Piperazines; Pyridones; Raltegravir Potassium; Tenofovir | 2022 |
Exposure to doravirine, lamivudine, tenofovir, and raltegravir in a patient with HIV after a Roux-en-Y gastric bypass.
Topics: Gastric Bypass; HIV Infections; Humans; Lamivudine; Raltegravir Potassium; Tenofovir | 2023 |